Investor Overview

Corporate Profile

Oncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Our strategy is to leverage our BioSymphony™ Platform to cost-effectively develop these biosimilars on an accelerated timeline, which is fundamental to our success and we believe positions us to be a leading biosimilar company.

Latest News

June 13, 2018

Oncobiologics Enters into First CDMO Contractmore >

June 08, 2018

Oncobiologics Closes Second Tranche of $15 Million Private Placementmore >

June 04, 2018

Stelis Biopharma and Oncobiologics to Unveil Bio2Source CDMO Offering at BIO 2018more >

Upcoming Events

There are currently no events scheduled.